The first-generation EGFR TKIs, gefitinib, erlotinib, icotinib, have been the standard-of-care as the first-line treatment in China for advanced NSCLC with EGFR-sensitizing mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.